Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV 6120/∆NS2/1030s Vaccine in Children
NCT03387137Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2017
- Primary completion
- Nov 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RSV 6120/ΔNS2/1030s in respiratory syncytial virus infection (RSV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants With Solicited Adverse Events at Day 28, Number of Participants With Unsolicited Adverse Events at Day 28 and 7 more. Started Oct 2017; status: completed.
02
Drugs
RSV 6120/ΔNS2/1030s
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03387137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387137.